After a decade of scant gains, some investors are now piling into pharmaceuticals as a combination of high yields and attractive valuations draw managers in, but is this the start of a decade-long move up?
Even in the context of their status as perennial cautious plays, drug companies have produced little in the way of capital growth over the past decade, particularly compared with some defensive peers....
Headed up by Penny Kyle
Ex-Standard life manager Angela Burns
Latest news and analysis
Talking Strategies: The number of companies in Asia with higher payout ratios have grown since the mid-1990s, but some investors remain wary of searching for income in Asia and Japan. In this video, Jupiter's Jason Pidcock and Dan Carter explain why this...